Cargando…

Response to “Comment on Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases”

Detalles Bibliográficos
Autores principales:	Moran, Kellyn, Null, Kyle, Huang, Zhongwen, Lissoos, Trevor, Kane, Sunanda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140747/ https://www.ncbi.nlm.nih.gov/pubmed/32173794 http://dx.doi.org/10.1007/s12325-020-01274-5

Ejemplares similares

Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases
por: Moran, Kellyn, et al.
Publicado: (2019)

Development and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study
por: Chen, Grace, et al.
Publicado: (2020)

Comment on: “Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases”
por: Woolcott, John, et al.
Publicado: (2020)

Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients
por: Khan, Nabeel, et al.
Publicado: (2017)

Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis
por: Fox, David, et al.
Publicado: (2022)

Intravenous Immunoglobulin Initiation in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims-based Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2023)

Molecules and Mechanisms
por: Betts, Kellyn
Publicado: (1995)

Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis
por: Anderson-Smits, Colin, et al.
Publicado: (2023)

Risk factors for postoperative infection after gastrointestinal surgery among adult patients with inflammatory bowel disease: Findings from a large observational US cohort study
por: Liang, Huifang, et al.
Publicado: (2018)

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis
por: Sussman, D., et al.
Publicado: (2017)

Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
por: Pardo, Gabriel, et al.
Publicado: (2022)

PB2081: TREATMENT PERSISTENCE AND ADHERENCE TO IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA: A GERMAN CLAIMS DATA ANALYSIS
por: Buske, C., et al.
Publicado: (2022)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
por: Engmann, Natalie J, et al.
Publicado: (2021)

Comments on claimed risk from metastable black holes
por: Giddings, Steven B., et al.
Publicado: (2008)

Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States
por: Patel, Haridarshan, et al.
Publicado: (2017)

Adherence and Persistence with First-Line Therapy and Compliance with Glaucoma Guidelines Using Japanese Health Care/Pharmacy Claims Database
por: Shirai, Chikako, et al.
Publicado: (2021)

Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis
por: Mahlich, Joerg, et al.
Publicado: (2021)

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
por: Carbery, Isabel, et al.
Publicado: (2023)

Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence
por: Bernick, Steven J, et al.
Publicado: (2010)

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
por: Halpern, Rachel, et al.
Publicado: (2011)

Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study
por: Nishimura, Rimei, et al.
Publicado: (2019)

The Challenge of Compliance and Persistence: Focus on Ulcerative Colitis
por: Kane, Sunanda V., et al.
Publicado: (2008)

Dubious Claims about Simplicity and Likelihood: Comment on Pinna and Conti (2019)
por: van der Helm, Peter A.
Publicado: (2020)

Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data
por: Jang, Yunjeong, et al.
Publicado: (2021)

The Return of the Repressed: The Persistent and Problematic Claims of Long-Forgotten Trauma
por: Otgaar, Henry, et al.
Publicado: (2019)

Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD)
por: Keyloun, Katelyn R., et al.
Publicado: (2017)

Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis
por: Brooks, Benjamin Rix, et al.
Publicado: (2022)

Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data
por: Kuwabara, Hiroyo, et al.
Publicado: (2015)

Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom
por: Liang, Huifang, et al.
Publicado: (2017)

A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review
por: Ungaro, Ryan, et al.
Publicado: (2019)

Direct and indirect predictors of medication adherence by adults with bipolar disorder
por: Cohen, B., et al.
Publicado: (2022)

Comment on persistent hyperinsulinemic hypoglycemia of infancy
por: Prashanth, G. P., et al.
Publicado: (2013)

Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis
por: Gor, Deval, et al.
Publicado: (2020)

Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies
por: Cai, Qian, et al.
Publicado: (2022)

Comments on "Claims of excess enthalpy by Fleischmann and Pons using simple cells made to boil"
por: Morrison, Douglas Robert Ogston
Publicado: (1993)

Geospatial Analysis of Statin Adherence Using Pharmacy Claims Data in the State of Michigan
por: Erickson, Steven R., et al.
Publicado: (2014)

Comments on Tegaserod Trial on Irritable Bowel Syndrome
por: Jung, Hye-Kyung
Publicado: (2010)

Direct and Indirect Predictors of Medication Adherence With Bipolar Disorder: Path Analysis
por: Cohen, Bar, et al.
Publicado: (2023)

Validity of Diagnostic Algorithms for Inflammatory Bowel Disease in Japanese Hospital Claims Data
por: Takahashi, Sayumi, et al.
Publicado: (2022)

Medication adherence in inflammatory bowel disease
por: Chan, Webber, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tp6v8ek443smrg20nlmsveadkq